3533 Carisoprodol A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202) 78-44-4 2576 C12H24N2O4 260.173610 White powder. 89-91°C 300 mg/L (at 25°C) Oral Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known. Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19. Route of Elimination: Carisoprodol is eliminated by both renal and non-renal routes. Half Life: 8 hours No indication of carcinogenicity to humans (not listed by IARC). For the relief of discomfort associated with acute, painful, musculoskeletal conditions. Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives 2009-07-30T17:58:45Z 2026-03-31T17:11:48Z Carisoprodol C07927 3419 Carisoprodol DB00395 true CCCC(C)(COC(N)=O)COC(=O)NC(C)C C12H24N2O4 InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) OFZCIYFFPZCNJE-UHFFFAOYSA-N 260.33 260.173607266 Exogenous Solid 2.1 HMDB14539 CHEMBL1233 2478 <p>Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter<br /> Products, Inc.</p> CHEM002508 DTXSID8024733 NS00008741 2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate